Monjuvi® (tafasitamab-cxix) – New indication
June 18, 2025 - Incyte announced the FDA approval of Monjuvi (tafasitamab-cxix), in combination with lenalidomide and rituximab, for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).
Download PDF